| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J3130 | Testosterone Enanthate | Testosterone Enanthate | 200 mg | Hormonal Therapy | Androgen | No | 1953 | Jan 1, 1982 | Jan 1, 2015 | No Longer Used | ||
| J2930 | Methylprednisolone Sodium Succinate | A-Methapred, SOLU-medrol | 125 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Jan 1, 1997 | Apr 17, 2024 | No Longer Used | |
| J8650 | Nabilone | Cesamet | 1 mg | Ancillary Therapy | Antiemetic | Cannabinoid | Yes | 1985 | Jan 1, 2007 | In Use | ||
| N/A | Vepdegestrant | Veppanu | 100mg, 200mg | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Yes | 2026 | In Use | |||
| J9276 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2024 | Jul 9, 2025 | In Use | ||
| N/A | Zidesamtinib | Jideytro | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, ALK, TRK | Yes | 2026 | In Use | |||
| NA | idelalisib | Zydelig | 100 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
| NA | lenvatinib | Lenvima | 10 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET | Yes | 2015 | In Use | |||
| NA | Thalidomide | Thalomid | 50 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| C9147 | Tremelimumab-actl | Imjudo | 1mg | Immunotherapy | Monoclonal Antibody | CTLA-4 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| C9175 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Jul 9, 2025 | Sep 8, 2025 | In Use | |
| NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
| NA | sonidegib | odozmo | 200 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2015 | In Use | |||
| NA | venetoclax | Venclexta | 10 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
| NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
| NA | Binimetinib | Mektovi | 15mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2018 | In Use | |||
| J9055 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Jan 1, 2005 | In Use | ||
| C9215 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Feb 12, 2004 | Dec 31, 2004 | No Longer Used | |
| NA | Erlotinib | Tarceva | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| J8999 | Chemotherapy - non specific | Prescription drug, oral, chemotherapeutic NOS | NA | Chemotherapy | Yes | In Use | ||||||
| S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan 1, 2002 | In Use | ||
| NA | Selpercatinib | Retevmo | 40mg, 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2020 | In Use | |||
| C9455 | Siltuximab | Sylvant | 10 mg | Immunotherapy | Monoclonal Antibody | IL-6 | No | 2014 | Jul 1, 2015 | Dec 31, 2015 | No Longer Used | |
| C9145 | Aprepitant | Aponvie | 1mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | No | 2023 | Mar 17, 2023 | Mar 18, 2026 | In Use | |
| J9400 | Ziv-aflibercept | Zaltrap | 1 mg | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | No | 2012 | Jan 1, 2014 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home